The anti-tumor drugs market operated well in 2006, and the total sales volume amounted to USD 34.6 billion, up 20.5% from a year earlier, and the growth margin ranked the first place among all the treatment categories to be the most important drive force for promoting the global drugs market. According to the increase trend in recent five years, it is forecasted that the anti-tumor drugs will probably be the unit product with the largest sales income in the global drugs market.
According to the forecast of IXIS, the molecule-targeted drugs will stand out singly, its annual compound growth rate (ACGR) will reach 23% in 2005-2010, and the market share will be from 39% in 2005 to 53.6% in 2010.
The total sales of anti-tumor drugs (except traditional Chinese medicine) in China amounted to RMB 6.002 billion in 2006, up 23.94% year-on-year. It is forecasted that the total sales of anti-tumor drugs (except traditional Chinese medicine) in China will reach RMB 7.6 billion in 2007, rising above 25% from a year earlier.
Sales Change Trend of China Anti-tumor Drugs (except Traditional Chinese Medicine)
Market Shares Change of China Anti-tumor Drugs (except Traditional Chinese Medicine)
|